# A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

> **NCT06962969** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Ibrance

## Key facts

- **NCT ID:** NCT06962969
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-30
- **Primary completion:** 2025-10-23
- **Final completion:** 2025-10-23
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06962969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06962969, "A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06962969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*